RT Journal Article
SR Electronic
T1 Variability in Radiotherapy Outcomes Across Cancer Types: A Comparative Study of Glioblastoma Multiforme and Low-Grade Gliomas
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.04.24309952
DO 10.1101/2024.07.04.24309952
A1 Veviorskiy, Alexander
A1 Mkrtchyan, Garik V
A1 Osipov, Andreyan N
A1 Ozerov, Ivan V
A1 Aliper, Alex
A1 Zhavoronkov, Alex
A1 Scheibye-Knudsen, Morten
YR 2024
UL http://medrxiv.org/content/early/2024/07/05/2024.07.04.24309952.abstract
AB Radiotherapy is a crucial treatment option for various cancers. However, the results of radiotherapy can vary widely across different cancer types and even among patients with the same type of cancer. This variability presents a major challenge in optimizing treatment strategies and improving patient survival. Here, we collected radiotherapy phenotype and expression data from 32 TCGA cancer datasets and performed overall survival analysis for 32 cancer types. Additionally, we conducted a signalling pathway enrichment analysis to identify key pathways involved in radiotherapy resistance and sensitivity. Our findings show that radiotherapy improves survival outcomes in certain cancer types, such as GBM, while worsening outcomes in others, such as LGG. Next, we focused on exploring the differences in radiotherapy outcomes between GBM and LGG, focusing on the molecular mechanisms contributing to these variations. The differential regulation of pathways related to programmed cell death, DNA repair, telomere maintenance, chromosome condensation, antiviral responses, and interferon signaling between GBM and LGG patients may elucidate the underlying reasons for these observed differences. These insights underscore the importance of personalized treatment approaches and the need for further research to improve radiotherapy outcomes in cancer patients.Competing Interest StatementInsilico Medicine is a company developing an AI-based end-to-end integrated pipeline for drug discovery and development and engaged in aging and cancer research. AV, IVO, AA, and AZ are affiliated with Insilico Medicine.Funding StatementThis work has been funded by the Danish Cancer society (#R368-A21521, #R302-A17379_001 and #R167-A11015_001), the Novo Nordisk Foundation Challenge Programme (NNF17OC0027812), the Nordea Foundation (02-2017-1749), the Lundbeck Foundation (R324-2019-1492), the Danish Ministry of Higher Education and Science (0238-00003B) and Insilico Medicine. The funders had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Gene expression and patient phenotype data for 32 TCGA cancers were collected from the UCSC Xena databaseI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data supporting the conclusions of the paper are available in the article and corresponding figures. TCGA datasets used in the paper are described in the materials and methods section.